Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10028 in Advanced Solid Tumors
NCT07596381Phase 1Not yet recruiting
- Sponsor
- InxMed
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IN10028 in solid tumor (advanced stage), sponsored by InxMed. Primary endpoints: Dose-Limiting Toxicities at 6 months, Maximum Tolerated Dose at 6 months and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
IN10028
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07596381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07596381.